Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Matthew McLean

Neurology Mobile, AL Medical Doctor

NPI 1699086199 CMS profile 1094689

1720 Spring Hill Ave, 3Rd Floor, Mobile, AL 36604

Open in the dashboard

General payments

$14,123

845 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$99,356 paid to institutions, not to them · program years 2023–2025

Through program year 2025, Matthew McLean of Mobile, AL is reported in the CMS Open Payments database as having received $14,123 across 845 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $99,356 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 79th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,062 165
2024 General $2,047 124
2023 General $1,625 101
2022 General $1,943 122
2021 General $2,334 151
2020 General $1,193 76
2019 General $1,919 106

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Matthew McLean
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Matthew McLean were reported at $3,062. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Matthew McLean Neurology median Middle half National median
2019 $1,919 $474 $118–$2,177 $163
2020 $1,193 $367 $82–$2,309 $114
2021 $2,334 $438 $104–$2,547 $132
2022 $1,943 $442 $103–$2,388 $149
2023 $1,625 $464 $119–$2,312 $160
2024 $2,047 $468 $119–$2,323 $164
2025 $3,062 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $3,233 251 payments
  2. UCB, Inc. $1,170 57 payments
  3. Novartis Pharmaceuticals Corporation $943 65 payments
  4. Lundbeck LLC $694 42 payments
  5. SK Life Science, Inc. $623 25 payments
  6. Biogen, Inc. $560 36 payments
  7. Eisai Inc. $547 27 payments
  8. Teva Pharmaceuticals USA, Inc. $542 33 payments
  9. Lilly USA, LLC $519 38 payments
  10. Allergan Inc. $439 28 payments
  11. Other $4,854 243 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $14,066 839 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $37 2 payments
  3. Education $20 4 payments
Products named General payments · program years 2019–2025
  1. UBRELVY $1,943 147 payments
  2. QULIPTA $1,364 120 payments
  3. VYEPTI $569 34 payments
  4. AIMOVIG $514 34 payments
  5. Leqembi $466 22 payments
  6. BOTOX $405 34 payments
  7. NURTEC ODT $383 30 payments
  8. ZAVZPRET $365 29 payments
  9. Briviact $363 16 payments
  10. KESIMPTA $336 15 payments
  11. Other $8,089 462 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 81 drugs

Part D claims

4,446

Median for Neurology: 833

Drug cost

$2,359,538

Median for Neurology: $202,670

Branded share of claims

23.1%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Zilbrysq Zilucoplan Sodium Brand 15 $603,113
Gammaplex Immun Glob G(Igg)/Gly/Iga 0-50 Brand 12 $359,827
Privigen Immun Glob G(Igg)/Pro/Iga 0-50 Brand 13 $338,989
Gamunex-C Immune Globul G/Gly/Iga Avg 46 Brand 33 $337,128
Nuplazid Pimavanserin Tartrate Brand 22 $106,142
Ingrezza Valbenazine Tosylate Brand 12 $95,252
Copaxone Glatiramer Acetate Brand 12 $68,584
Ubrelvy Ubrogepant Brand 46 $59,976
Nurtec Odt Rimegepant Sulfate Brand 43 $56,521
Emgality Pen Galcanezumab-Gnlm Brand 79 $56,061

The 10 drugs with the highest cost, of 81 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 48 billing codes

Paid by Medicare

$117,399

Of which drugs: $56,242

Medicare patients

412

Average age 74

Services billed

13,275

229 women, 183 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Ischemic heart disease 46%
Chronic kidney disease 42%
Diabetes 37%
Depression 29%
Alzheimer's or dementia 28%
Atrial fibrillation 27%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 16 9,755 $46,522

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
QULIPTA
$235 46 —
Leqembi
$172 — —
UBRELVY
$153 46 —
VYEPTI
$148 — —
EMGALITY
$142 79 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

845 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record